Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA).
Journal: Alimentary pharmacology & therapeutics
Published: November 03, 2025
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
Journal: Lancet (London, England)
Published: September 05, 2025
Diet and Lifestyle Interventions in Metabolic Dysfunction-Associated Fatty Liver Disease: A Comprehensive Review.
Journal: International journal of molecular sciences
Published: August 08, 2025
Accuracy of Velacur in Assessing MASLD and MASH Patients Using Biopsy as the Gold Standard.
Journal: Diagnostics (Basel, Switzerland)
Published: December 16, 2024
Metabolic dysfunction-associated steaotic liver disease self-management among the Hispanic/Latino population.
Journal: Frontiers in public health
Published: September 20, 2024
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.
Journal: Journal of hepatology
Published: April 20, 2023
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
Journal: The lancet. Gastroenterology & hepatology
Published: January 04, 2022
Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.
Journal: Journal of clinical and translational hepatology
Published: September 12, 2021
Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
Journal: Journal of hepatology
Published: November 19, 2019
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Journal: Lancet (London, England)
Published: October 04, 2019
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
Journal: Journal of hepatology
Published: September 06, 2019
Predictors of hospital re-admissions among Hispanics with hepatitis C-related cirrhosis.
Journal: Annals of gastroenterology
Published: May 17, 2016
Last Updated: 09/26/2026